Atai life sciences has been selected for addition to the nasdaq biotechnology index

New york, dec. 13, 2021 (globe newswire) -- atai life sciences n.v. (nasdaq: atai) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has been selected for addition to the nasdaq biotechnology index (nasdaq: nbi), effective as of market open on monday, december 20, 2021. the nbi is a stock market index made up of securities of nasdaq-listed companies classified according to the industry classification benchmark as either biotechnology or pharmaceuticals which also meet other eligibility criteria.
ATAI Ratings Summary
ATAI Quant Ranking